CDMO - August 9, 2017
Recipharm and LIDDS establish industrial manufacturing capabilities
Recipharm and LIDDS have together set up a manufacturing line for LIDDS’ novel prostate cancer drug, LiprocaDepot, at Recipharm in Solna. The manufacturing line is dedicated to the first product based on LIDDS’ NanoZolidtechnology. Clinical trial material has already been produced and the facility is ready for future commercial manufacturing of Liproca Depot or other […]
CDMO - April 25, 2017
Recipharm opens new GMP suite
Recipharm has opened a newly built GMP suite for clinical trial material (CTM) manufacture at its facility in Research Triangle Park, North Carolina, USA. The suite, which represents a $750k investment, is intended to produce CTM for clinical studies up to Phase II for non-sterile dosage forms, including metered dose inhalers and semi-solid topical products. […]
CDMO - April 18, 2017
Cobra Biologics expands gene therapy manufacturing operations
Cobra Biologics has announced the company’s expansion of operations at its sites in UK and Sweden. Over the next two years Cobra will invest up to £15m (165m SEK) on a phased expansion plan, supporting the company’s R&D expertise in developing rapid and cost effective viral vector and DNA plasmid production platforms. The initial phase, will […]
CDMO - March 27, 2017
Recipharm manufactures to the Japanese market
Recipharm has entered into a long term agreement with Sato Pharmaceutical for the commercial manufacture and delivery of Emla Patch to Japan. Emla Patch is used as a local anaesthetic product and will be launched under the business area of ethical pharmaceuticals at Sato. Recipharm’s facility in Karlskoga, Sweden will produce and deliver to Sato. […]
Acquisition - January 3, 2017
AGC Asahi Glass acquires CMC Biologics
Danish CDMO CMC Biologics and AGC Asahi Glass (AGC), a world-leading manufacturer of glass, chemicals and high-tech materials, have entered into a definitive agreement with CMC Biologics’ shareholders including Monitor Clipper Partners, European Equity Partners and Innoven Partenaires, by which AGC will acquire 100% of CMC Biologics’ shares. “With the high level of growth and […]
CDMO - December 5, 2016
Recipharm enters new collaboration
Recipharm is entering into a collaboration with Laccure AB for the commercial manufacture and delivery of Laccure Pessary. The new product, which has been developed to help women suffering from bacterial vaginosis, will be manufactured, packaged and distributed globally from Recipharm’s facility in Karlskoga that specialises in the production of semi-solid products. Over the past […]
